

Mitsuteru Natsuizaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3266550/publications.pdf>

Version: 2024-02-01

69
papers

2,691
citations

201385

27
h-index

189595

50
g-index

70
all docs

70
docs citations

70
times ranked

4372
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Clinical features of hepatocellular carcinoma with extrahepatic metastases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1781-1787. | 1.4 | 432 |
| 2 | Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. <i>Nature Communications</i> , 2017, 8, 1758. | 5.8 | 155 |
| 3 | Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. <i>Nature Protocols</i> , 2012, 7, 235-246. | 5.5 | 138 |
| 4 | Epidermal Growth Factor Receptor and Mutant p53 Expand an Esophageal Cellular Subpopulation Capable of Epithelial-to-Mesenchymal Transition through ZEB Transcription Factors. <i>Cancer Research</i> , 2010, 70, 4174-4184. | 0.4 | 128 |
| 5 | NOTCH1 and NOTCH3 Coordinate Esophageal Squamous Differentiation Through a CSL-Dependent Transcriptional Network. <i>Gastroenterology</i> , 2010, 139, 2113-2123. | 0.6 | 107 |
| 6 | Hypoxia activates the cyclooxygenase-2/prostaglandin E synthase axis. <i>Carcinogenesis</i> , 2010, 31, 427-434. | 1.3 | 104 |
| 7 | Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2016, 51, 733-740. | 2.3 | 103 |
| 8 | A NOTCH3-Mediated Squamous Cell Differentiation Program Limits Expansion of EMT-Competent Cells That Express the ZEB Transcription Factors. <i>Cancer Research</i> , 2011, 71, 6836-6847. | 0.4 | 99 |
| 9 | Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. <i>Experimental Cell Research</i> , 2007, 313, 3337-3348. | 1.2 | 72 |
| 10 | Insulin-like growth factor-binding protein-3 promotes transforming growth factor- β 1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. <i>Carcinogenesis</i> , 2010, 31, 1344-1353. | 1.3 | 72 |
| 11 | L-carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 910-922. | 2.0 | 67 |
| 12 | Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 2017, 38, 1073-1083. | 1.3 | 64 |
| 13 | 8-Hydroxy-2'-deoxyguanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1431-1436. | 1.4 | 58 |
| 14 | IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. <i>American Journal of Cancer Research</i> , 2014, 4, 29-41. | 1.4 | 50 |
| 15 | Human Amnion-Derived Mesenchymal Stem Cell Transplantation Ameliorates Dextran Sulfate Sodium-Induced Severe Colitis in Rats. <i>Cell Transplantation</i> , 2015, 24, 2601-2614. | 1.2 | 46 |
| 16 | EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. <i>Cancer Biology and Therapy</i> , 2015, 16, 933-940. | 1.5 | 46 |
| 17 | Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1 α -mediated mRNA transcription and continuous protein synthesis. <i>FASEB Journal</i> , 2012, 26, 2620-2630. | 0.2 | 44 |
| 18 | Inhibition of Notch signaling enhances transdifferentiation of the esophageal squamous epithelium towards a Barrett's-like metaplasia via KLF4. <i>Cell Cycle</i> , 2014, 13, 3857-3866. | 1.3 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60. | 0.7 | 36 |
| 20 | Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977. | 1.8 | 35 |
| 21 | CTNNB1 mutational analysis of solid-pseudopapillary neoplasms of the pancreas using endoscopic ultrasound-guided fine-needle aspiration and next-generation deep sequencing. <i>Journal of Gastroenterology</i> , 2015, 50, 203-210. | 2.3 | 33 |
| 22 | Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor- κ B/mitogen-activated protein kinase. <i>Carcinogenesis</i> , 2014, 35, 272-281. | 1.3 | 32 |
| 23 | Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129. | 2.3 | 32 |
| 24 | Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304. | 1.8 | 32 |
| 25 | Intrahepatic artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. <i>Abdominal Imaging</i> , 2015, 40, 1492-1499. | 2.0 | 31 |
| 26 | Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <i>Hepatology Research</i> , 2017, 47, 1127-1136. | 1.8 | 31 |
| 27 | Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. <i>PLoS ONE</i> , 2018, 13, e0209615. | 1.1 | 29 |
| 28 | Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180. | 2.3 | 29 |
| 29 | Metformin Regulates the Expression of CD133 Through the AMPK-CEBP β Pathway in Hepatocellular Carcinoma Cell Lines. <i>Neoplasia</i> , 2019, 21, 545-556. | 2.3 | 28 |
| 30 | Analysis of the optimal psoas muscle mass index cutoff values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. <i>Hepatology Research</i> , 2020, 50, 715-725. | 1.8 | 28 |
| 31 | Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. <i>Hepatology Research</i> , 2016, 46, 1294-1303. | 1.8 | 27 |
| 32 | Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 101. | 3.5 | 27 |
| 33 | A pivotal role of Kr μ ppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1453-1461. | 1.5 | 22 |
| 34 | Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788. | 1.4 | 22 |
| 35 | Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108. | 1.8 | 21 |
| 36 | Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649. | 2.3 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. <i>Carcinogenesis</i> , 2021, 42, 58-69. | 1.3 | 21 |
| 38 | Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2017, 89, 857-866. | 2.5 | 20 |
| 39 | High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681. | 1.8 | 20 |
| 40 | Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989. | 1.8 | 20 |
| 41 | Notch receptor inhibition reveals the importance of cyclin D1 and Wnt signaling in invasive esophageal squamous cell carcinoma. <i>American Journal of Cancer Research</i> , 2012, 2, 459-75. | 1.4 | 20 |
| 42 | Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86. | 2.3 | 19 |
| 43 | Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. <i>Hepatology Research</i> , 2019, 49, 1207-1217. | 1.8 | 19 |
| 44 | Diffuse Large B-cell Lymphoma with Massive Portal Vein Tumor Thrombosis in a Patient with Alcoholic Cirrhosis: A Case Report and Literature Review. <i>Internal Medicine</i> , 2009, 48, 805-808. | 0.3 | 17 |
| 45 | ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 593-599. | 1.0 | 17 |
| 46 | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760. | 1.1 | 17 |
| 47 | Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845. | 1.8 | 15 |
| 48 | Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538. | 1.8 | 15 |
| 49 | Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888. | 0.7 | 13 |
| 50 | Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. <i>Hepatology Research</i> , 2020, 50, 1196-1200. | 1.8 | 11 |
| 51 | Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633. | 1.7 | 10 |
| 52 | Sensitive Assay for Quantification of Hepatitis B Virus Mutants by Use of a Minor Groove Binder Probe and Peptide Nucleic Acids. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4487-4494. | 1.8 | 9 |
| 53 | Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285. | 1.8 | 8 |
| 54 | Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114. | 0.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207. | 1.6 | 8 |
| 56 | Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415. | 1.7 | 8 |
| 57 | Hepatosplenic Gamma-delta T-cell Lymphoma Associated with Epstein-Barr Virus. <i>Internal Medicine</i> , 2014, 53, 2079-2082. | 0.3 | 6 |
| 58 | Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. <i>Journal of Viral Hepatitis</i> , 2021, 28, 755-763. | 1.0 | 6 |
| 59 | Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. <i>Scientific Reports</i> , 2021, 11, 16616. | 1.6 | 6 |
| 60 | Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232. | 1.7 | 6 |
| 61 | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947. | 0.3 | 5 |
| 62 | MMP7 and activation of IGF-1R: A new insight into anti-EGFR therapeutic resistance in metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2011, 11, 184-187. | 1.5 | 4 |
| 63 | The nuclear protein Artemis promotes AMPK activation by stabilizing the LKB1-AMPK complex. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 790-795. | 1.0 | 4 |
| 64 | Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802. | 0.3 | 4 |
| 65 | Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2076-2087. | 0.8 | 4 |
| 66 | Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728. | 1.1 | 3 |
| 67 | FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 372-380. | 1.5 | 3 |
| 68 | Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154. | 1.8 | 1 |
| 69 | Can Stressed Blood Cells Tell Cancer Risk in Inflammatory Bowel Diseases?. <i>Gastroenterology</i> , 2009, 137, 2174-2175. | 0.6 | 0 |